STAT3 and AL amyloidosis: A study demonstrated that the anticancer effect of β-caryophyllene oxide was mediated through interfering with the activation of STAT3 in carcinoma cells, such as multiple myeloma cells (U266) and human prostate cancer cells (DU145).